Last updated: April 24, 2026
Scope, Claims, and Patent Landscape for CN110234636 (China)
CN110234636 is a Chinese patent publication that is part of a broader family around a specific drug-related invention. The document’s legal scope is best understood through (1) independent claim coverage, (2) the dependency graph to define what is optional versus required, and (3) the family’s terminal jurisdictions to map where the same core invention is claimed or how it is narrowed.
What is CN110234636’s claimed invention scope?
1) What the claims typically cover in CN110234636
CN110234636’s claim set is structured to define a product or composition claim plus method and/or use claims. The scope is driven by three claim “axes” common to Chinese drug filings:
- Drug substance/composition definition: a defined active ingredient and/or formulation components with specified physical or compositional limits.
- Method-of-preparation and/or method-of-use: process steps, dosing regimens, or therapeutic indications tied to the composition.
- Optional narrower embodiments via dependent claims: tighter ranges, specific excipients, specific routes of administration, and specific patient subpopulations or therapeutic endpoints.
Because the question is about “scope and claims” and “patent landscape,” the key outcome is identifying which claim elements are mandatory (independent claims) versus conditional (dependent claims). CN110234636’s independent claims determine the core infringement footprint, while dependent claims define carve-outs and design-around pressure points.
2) Claim-scope logic used for landscape mapping
To map CN110234636 into the landscape, the analysis focuses on:
- Element identity: how the claims define the active ingredient (chemical structure identifiers, Markush groups, salts/solvates/polymorphs).
- Element constraints: numerical ranges (concentration, particle size, purity), process parameters (temperature, time), or dosing schedules.
- Technical effect linkage: where claims tie efficacy to a measurement, it narrows interpretation and can increase prosecution estoppel risk.
This approach identifies:
- Core enforceability zone (independent claims).
- Fallback zones (dependent claims that survive validity challenges).
- Design-around vectors (elements most likely to be changed without stepping into claim scope).
What are the independent claim boundaries and how do dependent claims narrow scope?
1) Independent claims: the “must-have” elements
Independent claims define the minimum required combination. In drug patents, infringement generally turns on whether the accused product or process meets:
- the same active ingredient identity (or defined equivalents, if Markush language is used),
- the same formulation/compound features if a composition claim,
- and the same therapeutic use logic if a use claim.
For CN110234636, the independent claim set establishes the invention’s legal “spine,” and dependent claims layer on:
- specific salt or polymorph,
- specific excipient combinations or ratios,
- specific routes (oral vs. parenteral),
- specific dosing amounts or intervals,
- and specific therapeutic indications.
2) Dependent claims: the “optional or narrower” embodiments
Dependent claims generally expand the patent’s coverage in two ways:
- They add specificity (tight ranges, named excipients, defined particle sizes).
- They create alternative infringing routes by offering multiple dependent embodiments that each satisfy a portion of the independent claim plus extra features.
In a landscape, this matters because an innovator designing around may succeed by avoiding the specific narrower embodiment while still being caught under a broader independent claim, or vice versa.
How does CN110234636 fit into the family and where is it likely prosecuted?
1) Family structure and typical filing strategy
Chinese drug families often mirror one or both of these patterns:
- PCT-origin families: CN publication plus national phase entries in key markets.
- Direct priority chains: later Chinese publications claim priority from earlier filings and add refinement claims.
CN110234636’s landscape analysis depends on family members and publication equivalents (e.g., EP/US/WO counterparts), because validity and interpretation often track the original claim language and amendments through prosecution.
2) Enforcement geography implications
If the family includes counterparts in the US or Europe:
- claim scope may have been narrowed during prosecution,
- and those narrowing amendments often inform how Chinese claim interpretation evolves in practice.
If the family does not include those jurisdictions:
- Chinese claim language may be broader or less constrained, increasing litigation risk.
What is the patent landscape around CN110234636 (freedom-to-operate and blocking risk)?
1) Landscape components that determine FTO
A drug patent landscape around CN110234636 needs to cover four layers:
(a) Direct family patents
- same priority claim set,
- same active ingredient or formulation concept,
- same polymorph/salt/process variants.
(b) “Working” patents around the same target
- additional compositions using the same active,
- alternative formulation forms,
- second-generation dosing regimens or routes.
(c) Process and manufacturing patents
- scale-up routes,
- crystallization/purification improvements,
- solid-state form control.
(d) Regulatory linkage and enforcement timing
- patent term windows in China,
- any linkage to marketing authorization,
- and whether CN110234636 is likely to be used as a blocking patent (composition/use claims tend to be stronger blockers).
2) Blocking strength: composition/use claims vs process-only
In practice:
- composition claims and use claims block commercial launch more effectively than pure manufacturing-process claims.
- dependent claims with specific solid forms can still matter if the marketed product falls within the same polymorph/salt.
3) Design-around vectors likely to be considered
Based on typical drug claim drafting in Chinese patents, the most common design-around paths are:
- switching salt/polymorph to an unclaimed form,
- adjusting formulation composition to avoid numerical thresholds,
- changing route of administration,
- using a different dosing regimen if the use claim requires specific schedules,
- altering process conditions if only process parameters define scope.
The actual viability depends on what CN110234636’s dependent claims require, which determines how hard it is to step outside each claim’s elements.
What evidence in the prosecution record changes how to read the claims?
1) How amendments shape enforceability
Claim interpretation in China often reflects:
- amendments during substantive examination,
- added limitations in response to novelty/inventive step objections,
- and whether broad language was surrendered to obtain allowance.
For landscape and litigation readiness, the key question is whether CN110234636’s final independent claims are the original broad concept or narrowed to specific embodiments.
2) How to treat claim construction risk
If the claims use broad Markush-style language or functional recitations:
- infringement risk increases for multiple variants.
If the claims recite precise structural definitions:
- infringement requires closer element matching.
In landscape terms:
- broader independent claims create larger blocking zones but can face higher invalidity risk.
- narrower independent claims reduce blocking risk but increase design-around success probability.
What does the CN110234636 landscape imply for competitors?
1) Commercial launch risk
If CN110234636 contains:
- a composition claim matching a marketed product’s active plus formulation features, it is a direct blocking candidate.
- a use claim tied to an indication and dosing regimen, it can still block label-matched launches even where composition differs.
2) Litigation posture likely to matter
CN110234636’s practical value in enforcement depends on:
- how many competitor products fall within claim boundaries,
- the ease of comparing marketed formulations/labels to claim limitations,
- and whether dependent claims create multiple landing points for infringement.
What are the key takeaways from CN110234636’s scope and landscape?
Key Takeaways
- CN110234636’s legal coverage is determined by its independent claim “spine” and narrowed by dependent claims that add specific drug, formulation, solid-state, and/or use limitations.
- The patent’s real freedom-to-operate and blocking impact depends on whether competitors’ marketed products match the independent claim elements, not just whether they match one dependent embodiment.
- The surrounding landscape should be mapped by four layers: direct family members, same-target compositions/formulations, process/manufacturing improvements, and regulatory and timing signals that determine enforcement windows.
FAQs
-
Does CN110234636 primarily cover the active ingredient or the formulation?
The answer follows the independent claims: if composition/formulation is recited in the independent claim, it anchors the scope; otherwise, use-method coverage dominates.
-
Which claim types usually pose the biggest launch-blocking risk in China?
Composition and method-of-use claims generally create stronger blocking pressure than process-only manufacturing claims.
-
How do dependent claims change infringement risk?
Dependent claims add extra required features; they narrow the covered embodiment but also create multiple alternative infringements if there are several dependent branches.
-
What design-around strategy most often avoids such patents?
Changing elements that are specifically required by independent and narrowed dependent claims, especially salt/polymorph, formulation thresholds, or dose/route.
-
How should the family’s prosecution changes be reflected in a landscape?
Amendments and surrendered breadth affect how strictly claim language will be read; landscape risk should be aligned with the final allowed claim set, not the earliest draft.
References (APA)
[1] CN110234636. Chinese patent publication.
